The Company‟s Board of Directors has proposed a final dividend of 20 paise /share of face value of Rs. 1each.
Granules India Ltd., a growing pharmaceutical manufacturing company, announced results for its fourth quarter ended 31st March, 2016.
Financial Highlights for Q4 FY16 (Consolidated):-
Revenue: Rs. 373 Cr., an increase of 5% compared to Rs. 355 Cr. in Q4FY15
EBITDA: Rs. 80 Cr., an increase of 55% compared to Rs. 52 Cr. in Q4FY15
Net Profit: Rs. 33 Cr., an increase of 48% compared to Rs. 22 Cr. in Q4FY15
The Company‟s Board of Directors has proposed a final dividend of 20 paise /share of face value of Rs. 1each.
“While we were strengthening our foundation last year, we simultaneously worked towards building a
momentum for the future. We had a gentle top line growth but bottom line excelled with improved margins, validating our excellence in operational efficiency. Last year, we witnessed the commercialization of ourCRAMS business, ANDA approval for Ibuprofen Rx and the construction of a new capacity in addition to augmentation of R&D initiatives. This year and the year to come, we look forward to build a strong and agileGranules India‟, which will emerge as an efficient pharmaceutical manufacturing partner with a key focuson Research and Development.” said Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India Limited.
No comments:
Post a Comment